- Trial phase
- Phase 2 (topline readout complete; confirmatory Phase 3 announced but not yet started)
- Time to market
- Unknown and several years away, a confirmatory Phase 3 program has not even started; the completed Phase 2 CELIA trial's estimated overall completion is January 2029, so a registration and launch would come later than that if Phase 3 succeeds.
- Why 4/10
- No hard, dated binary is scheduled in the next ~12 months: the Phase 2 CELIA topline (May 14, 2026) and AAIC presentation (July 14, 2026) have already passed, and Biogen's planned confirmatory Phase 3 has no announced start or readout date, so this is long-dated optionality at a large-cap with multiple other programs (3-5 zone; scored 4).
Watch for Biogen's announcement of the Phase 3 program design, start date, and endpoints, that will be the next share-moving event, but it is likely months away and not a binary. Near-term BIIB stock moves are driven mostly by the commercial franchises (LEQEMBI, SPINRAZA) and other pipeline news, not diranersen, so treat this as years-out call-option value rather than a trade catalyst.
Price Chart
Executive Summary
Diranersen (development code BIIB080) is Biogen's investigational anti-tau antisense oligonucleotide for early Alzheimer's disease, the most advanced tau-targeting ASO in the space. The Phase 2 CELIA study missed its primary endpoint (dose response on CDR-SB), yet showed reportedly strong CSF tau reduction (~50-65%) and a cognitive-slowing signal on CDR-SB (~26% at 60 mg) in pre-specified analyses, which Biogen presented at AAIC 2026 as proof of concept and used as the basis to plan a confirmatory Phase 3. This is a mixed read: a statistical miss on the main endpoint but enough biomarker/cognitive signal to justify advancement.
How It Works
Diranersen is an antisense oligonucleotide (ASO), a short synthetic strand of genetic material injected into the spinal fluid that binds to the tau gene's messenger RNA and reduces how much tau protein the body produces. Tau is the protein that forms destructive tangles inside brain cells in Alzheimer's, and it tracks more closely with cognitive decline than the amyloid plaques targeted by existing drugs. Because it is delivered by lumbar puncture (spinal injection) rather than an IV, it is an invasive, specialized administration.
Trial Status
The Phase 2 CELIA study (NCT05399888, 416 patients with early Alzheimer's, intrathecal BIIB080 vs placebo, status ACTIVE_NOT_RECRUITING) reported topline on May 14, 2026: it MISSED its primary endpoint (dose response on CDR-SB), but pre-specified analyses showed clinical slowing on CDR-SB (reported ~26% at 60 mg) and robust CSF tau reduction (reported ~50-65%). Full results presented July 14, 2026 at AAIC 2026; Biogen called it Phase 2 proof of concept and said it will advance diranersen into confirmatory Phase 3 development.
The Two-Sided Case
Upcoming Catalysts
- Announcement of Phase 3 trial design, endpoints, and start date (no date given by Biogen)
- Any further CELIA subgroup/sensitivity analyses at future medical conferences
- Regulatory interactions (e.g., FDA alignment on the Phase 3 program) disclosed via press release or 10-Q/8-K
- Quarterly earnings commentary on pipeline priorities (next earnings release expected late October 2026, based on prior 10-Q cadence)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Biogen Inc. Press Release BIIB ·Originating report